Biomarkers are now routinely used in determining the clinical outcome, diagnosis, prognosis, staging and treatment of human cancers. In May 2017, the FDA for the first time in its history, approved the checkpoint blockade drug Pembrolizumab, solely for biomarker indications instead of tumor histopathology or location. We developed a search tool to discover important biomarkers in human malignancies. We use breast and prostate cancer to demonstrate this new search tool.

Learning Objective 1: Using a newly developed search tool, we wanted to find out what the top biomarkers are in breast cancer and prostate cancer reported in PubMed.


Paul Fontelo, Nantional Library of Medicine
Fang Liu (Presenter)
Nantional Library of Medicine

Presentation Materials: